JP2011504874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504874A5 JP2011504874A5 JP2010520356A JP2010520356A JP2011504874A5 JP 2011504874 A5 JP2011504874 A5 JP 2011504874A5 JP 2010520356 A JP2010520356 A JP 2010520356A JP 2010520356 A JP2010520356 A JP 2010520356A JP 2011504874 A5 JP2011504874 A5 JP 2011504874A5
- Authority
- JP
- Japan
- Prior art keywords
- vertebrate
- target gene
- chylomicron
- nucleic acid
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 16
- 108010004103 Chylomicrons Proteins 0.000 claims 9
- 230000014509 gene expression Effects 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 229940122498 Gene expression inhibitor Drugs 0.000 claims 7
- 108010004942 Chylomicron Remnants Proteins 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 235000003642 hunger Nutrition 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- -1 antagomir Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 108091008104 nucleic acid aptamers Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000006863 thiophosphorylation reaction Methods 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99079607P | 2007-11-28 | 2007-11-28 | |
| US60/990,796 | 2007-11-28 | ||
| PCT/JP2008/003523 WO2009069313A1 (en) | 2007-11-28 | 2008-11-28 | System for delivering nucleic acids for suppressing target gene expression by utilizing endogenous chylomicron |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504874A JP2011504874A (ja) | 2011-02-17 |
| JP2011504874A5 true JP2011504874A5 (enExample) | 2012-01-19 |
| JP5429884B2 JP5429884B2 (ja) | 2014-02-26 |
Family
ID=40678225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520356A Active JP5429884B2 (ja) | 2007-11-28 | 2008-11-28 | 内因性カイロミクロンを利用した、標的遺伝子の発現を抑制する核酸のデリバリーシステム |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8329670B2 (enExample) |
| EP (1) | EP2215229B1 (enExample) |
| JP (1) | JP5429884B2 (enExample) |
| CN (1) | CN101874111B (enExample) |
| WO (1) | WO2009069313A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5892658B2 (ja) * | 2010-08-20 | 2016-03-23 | 国立大学法人 東京医科歯科大学 | 経大腸吸収用医薬組成物 |
| CN102198276B (zh) * | 2011-04-01 | 2013-03-27 | 山西医科大学 | 乳糜微粒作为肝脏靶向基因治疗载体的应用 |
| CN102198277A (zh) * | 2011-04-01 | 2011-09-28 | 山西医科大学 | 一种基因治疗肝癌的双靶向性载体及其制备方法 |
| WO2014187315A1 (zh) * | 2013-05-21 | 2014-11-27 | 成都先导药物开发有限公司 | 一种化合物给药前体及药物载体制剂 |
| JP6276390B2 (ja) * | 2013-05-21 | 2018-02-07 | 成都先導薬物開発有限公司 | 化合物の細胞膜透過の方法 |
| CA3120508A1 (en) | 2013-10-28 | 2015-05-07 | Dots Technology Corp. | Allergen detection |
| JP2015199264A (ja) | 2014-04-08 | 2015-11-12 | ブラザー工業株式会社 | 液体吐出装置 |
| WO2016152980A1 (ja) * | 2015-03-24 | 2016-09-29 | 国立大学法人岐阜大学 | オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法 |
| JP6950958B2 (ja) * | 2015-12-01 | 2021-10-13 | 国立大学法人 東京医科歯科大学 | 核酸を含む経腸投与用組成物 |
| JP7692829B2 (ja) | 2019-07-30 | 2025-06-16 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4331670A1 (de) * | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
| DE4338704A1 (de) * | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
| CA2264012C (en) * | 1996-08-13 | 2011-04-26 | Chiron Corporation | Compositions and methods for polynucleotide delivery |
| CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| JP2005168485A (ja) | 2003-11-20 | 2005-06-30 | Tsutomu Suzuki | ｓｉＲＮＡの設計方法 |
| JP4706019B2 (ja) | 2005-07-08 | 2011-06-22 | 国立大学法人東京農工大学 | アプタマーの同定方法 |
-
2008
- 2008-11-28 WO PCT/JP2008/003523 patent/WO2009069313A1/en not_active Ceased
- 2008-11-28 JP JP2010520356A patent/JP5429884B2/ja active Active
- 2008-11-28 EP EP08853348.4A patent/EP2215229B1/en not_active Not-in-force
- 2008-11-28 CN CN200880117687XA patent/CN101874111B/zh not_active Expired - Fee Related
-
2010
- 2010-05-26 US US12/787,552 patent/US8329670B2/en active Active
-
2012
- 2012-11-05 US US13/668,668 patent/US8507458B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504874A5 (enExample) | ||
| ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
| Hatakeyama et al. | The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice | |
| JP5872988B2 (ja) | 標的遺伝子の発現を抑制する組成物 | |
| Michell et al. | HDL and microRNA therapeutics in cardiovascular disease | |
| WO2014022739A3 (en) | Modified rnai agents | |
| WO2011153493A3 (en) | Biodegradable lipids for the delivery of active agents | |
| US11312954B2 (en) | Transkingdom platform for therapeutic nucleic acid delivery | |
| CN101874111B (zh) | 利用内源性乳糜微粒递送用于抑制靶基因表达的核酸的体系 | |
| WO2013074974A3 (en) | Modified rnai agents | |
| HK1200837A1 (en) | Compositions and methods for silencing aldehyde dehydrogenase | |
| JP2022501064A (ja) | ケイ素を含有するカチオン性脂質 | |
| WO2016145008A2 (en) | Mirna for treatment of breast cancer | |
| Tian et al. | The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice | |
| de Fougerolles et al. | siRNA and the lung: research tool or therapeutic drug? | |
| Zhou et al. | MicroRNA-21 abrogates palmitate-induced cardiomyocyte apoptosis through caspase-3/NF-κB signal pathways | |
| US20110293653A1 (en) | Antagonists of mir-155 for the treatment of inflammatory liver disease | |
| Gedefaw et al. | Targeting inflammasome activation in COVID-19: delivery of RNA interference-based therapeutic molecules | |
| Abdel Rhman et al. | The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy | |
| Ungaro et al. | PEI-engineered respirable particles delivering a decoy oligonucleotide to NF-κB: inhibiting MUC2 expression in LPS-stimulated airway epithelial cells | |
| JP5685764B2 (ja) | ミトコンドリア機能向上剤 | |
| EP3238727B1 (en) | Non-aggregating immunostimulatory oligonucleotides | |
| Ballarín-González et al. | Clinical translation of RNAi-based treatments for respiratory diseases | |
| US20220267769A1 (en) | Medical uses, methods and uses | |
| JP7431728B2 (ja) | ＥＮａＣ発現の調節因子 |